FDA faces sensitive challenge with review of DMD drug

An FDA advisory committee hearing for a Duchenne muscular dystrophy (DMD) drug has been postponed due to the major snowfall on the East Coast, and it is likely to be rescheduled within the month. DMD is a rare and fatal genetic disorder that affects about 15,000 young boys in the United States, with no approved drugs to treat it.